estrogen receptor
The firm is seeing the fruit of a two-year investment in transitioning from a research lab to a clinical focus.
The firm's Q-plasia OncoReader Breast is the first in its line of products for different cancers, including skin, lung, and ovarian cancer.
Meeting presentations supported tweaking the clinical interpretation of Genomic Health's Oncotype DX and bolstered Biotheranostics' Breast Cancer Index.
The Dutch multinational is now on track to introduce a kitted version of the assay, which can be run on standard quantitative PCR equipment, by the end of the year.
Biotheranostics Settles False Claims Allegations With DOJ for $2M
The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for patients who had not been in remission for five years and who had not been taking tamoxifen.